	US 11,672,872 B2
	Anti-transferrin receptor antibody and uses thereof
Romesh R. Subramanian, Framingham, MA (US); Mohammed T. Qatanani, Waltham, MA (US); Timothy Weeden, Waltham, MA (US); Cody A. Desjardins, Waltham, MA (US); Brendan Quinn, Boston, MA (US); and John Najim, Waltham, MA (US)
Assigned to Dyne Therapeutics, Inc., Waltham, MA (US)
Filed by Dyne Therapeutics, Inc., Waltham, MA (US)
Filed on Jul. 8, 2022, as Appl. No. 17/811,401.
Claims priority of provisional application 63/220,043, filed on Jul. 9, 2021.
Prior Publication US 2023/0051954 A1, Feb. 16, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/44 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2881 (2013.01) [A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/55 (2013.01); C07K 2317/92 (2013.01)]

21 Claims

1. An antibody that binds to human transferrin receptor (TfR), wherein the antibody is a Fab and comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 101 and a light chain comprising the amino acid sequence of SEQ ID NO: 90.